MetaCap

Apnimed (APMD) vs Janux Therapeutics (JANX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Apnimed is the larger company by market cap ($669.8 million vs $616.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APMD-35.64%JANX-33.55%
+37%-5%-47%
Jul 31, 20261 yearNov 20, 2026
APMD-35.64%JANX-33.55%
+37%-3%-43%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APMD versus JANX key metrics
MetricAPMDJANX
Share price$16.09$10.08
Market cap$669.84M$616.73M
1-day change-6.70%-2.04%
YTD return—-26.96%
1-year return—-65.00%
5-year return—-42.92%
P/E ratio (TTM)1.21—
EPS (TTM)$13.34$-1.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$10.00M
Revenue growth (YoY)—-5.55%
Net income (latest FY)—$-113.63M
Operating margin—-1576.67%
Net margin—-1136.25%
52-week high$35.29$35.34
52-week low$13.88$10.05
Distance from 52-week high-54.41%-71.48%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+210.75%+228.77%
Average volume458.58K961.56K
Shares outstanding41.63M61.18M
Employees112114
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Apnimed

APMD stock →

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.

Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees

About Janux Therapeutics

JANX stock →

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 114 employees

APMD vs JANX FAQ

Which is bigger, Apnimed or Janux Therapeutics?

Apnimed (APMD) is larger, with a market capitalization of $669.84M compared with $616.73M for Janux Therapeutics (JANX).

Are Apnimed and Janux Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons